Home > Search Results
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 4

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women

Advanced (or metastatic) breast cancer is cancer that has spread beyond the breast and regional lymph node areas. Breast cancer can progress to metastatic disease despite the person undergoing a range of therapies given after initial treatment, such as surgery, chemotherapy or radiation therapy. Metastatic breast cancer is treatable but it is not curable. Most breast cancer is sensitive to the female hormone oestrogen. Sensitive cancer cells need oestrogen to stay alive and removal of oestrogen from the body, or stopping any circulating oestrogen getting to the cancer cells, is very effective treatment for hormone‐sensitive breast cancers. Endocrine (hormonal) therapy removes the influence of oestrogen on breast cancer cells. Hormonal treatments for advanced breast cancer include tamoxifen, the progestins megestrol acetate and medroxyprogesterone acetate, and aromatase inhibitors (AIs). AIs reduce the body's ability to make (synthesise) oestrogen and have tumour‐regressing effects. The AIs in current clinical use include anastrozole, exemestane, and letrozole.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2009

Aromatase inhibitors for subfertility treatment in women with polycystic ovary syndrome

Review question: Cochrane authors examined the evidence about aromatase inhibitors for subfertile women with polycystic ovary syndrome (PCOS).

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2014

Efficacy and safety of trastuzumab in metastatic breast cancer

Tumours characterised by the presence of the HER2 protein are found in about one in five women with metastatic breast cancer. These tend to be more aggressive and the prognosis and choice of treatment are affected. Trastuzumab (Herceptin®) is a targeted biological drug (a monoclonal antibody) that attaches to the HER2 protein, blocking the growth of malignant cells.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2014

Breast Cancer Prevention (PDQ®): Patient Version

Expert-reviewed information summary about factors that may increase the risk of developing breast cancer and about research aimed at the prevention of this disease.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: July 25, 2014

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...